{"transactions":[{"id":2312782,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":128571,"kind":"person","name":"Dawson Michael John","position":1,"cik":"0001849790","reported_name":"Dawson Michael John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-31T12:31:44.000Z","date":"2022-03-29","kind":"purchase","acquired":true,"shares":15000,"price":1.1395,"value":17092.5,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-22-021681","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000120919122021681/doc4.xml","form_type":"4"}},{"id":2381944,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":128571,"kind":"person","name":"Dawson Michael John","position":1,"cik":"0001849790","reported_name":"Dawson Michael John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-22T22:54:40.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":32400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares underlying the Stock Option shall vest and become exercisable on each three-month anniversary of the vesting commencement date and if there is no corresponding day, the last day of the month."}],"balance_after":32400,"derivative":{"exercise_price":0.95,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":32400},"source":{"system":"sec-edgar","filing":"0001209191-22-011853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000120919122011853/doc4.xml","form_type":"4"}},{"id":2404156,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":128571,"kind":"person","name":"Dawson Michael John","position":1,"cik":"0001849790","reported_name":"Dawson Michael John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-10T23:40:52.000Z","date":"2021-11-18","kind":"grant","acquired":true,"shares":39294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares underlying the Stock Option shall vest and become exercisable on each three-month anniversary of the vesting commencement date and if there is no corresponding day, the last day of the month."}],"balance_after":39294,"derivative":{"exercise_price":2.32,"expiration_date":"2031-11-17","underlying":"Common Stock","underlying_shares":39294},"source":{"system":"sec-edgar","filing":"0001209191-22-008596","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000120919122008596/doc4.xml","form_type":"4"}},{"id":2735744,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":128571,"kind":"person","name":"Dawson Michael John","position":1,"cik":"0001849790","reported_name":"Dawson Michael John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-29T21:46:49.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":2800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Received in the Merger in exchange for a stock option to acquire 103,000 shares of LBS common stock for $0.73 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested in four equal quarterly installments from the vesting commencement date."}],"balance_after":2800,"derivative":{"exercise_price":26.85,"expiration_date":"2030-02-19","underlying":"Common Stock","underlying_shares":2800},"source":{"system":"sec-edgar","filing":"0001209191-21-029066","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000120919121029066/doc4.xml","form_type":"4"}},{"id":2735743,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":128571,"kind":"person","name":"Dawson Michael John","position":1,"cik":"0001849790","reported_name":"Dawson Michael John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-29T21:46:49.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":1962,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received in the Merger in exchange for a stock option to acquire 72,200 shares of LBS common stock for $1.12 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested in four equal quarterly installments from the vesting commencement date."}],"balance_after":1962,"derivative":{"exercise_price":41.2,"expiration_date":"2029-03-22","underlying":"Common Stock","underlying_shares":1962},"source":{"system":"sec-edgar","filing":"0001209191-21-029066","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000120919121029066/doc4.xml","form_type":"4"}},{"id":2735742,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":128571,"kind":"person","name":"Dawson Michael John","position":1,"cik":"0001849790","reported_name":"Dawson Michael John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-29T21:46:49.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":5084,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in the Merger in exchange for a stock option to acquire 187,000 shares of LBS common stock for $1.12 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests according to the following schedule: 33% of the shares underlying the option vests on grant date and the remaining 67% vests in eight equal quarterly installments thereafter beginning on March 31, 2019."}],"balance_after":5084,"derivative":{"exercise_price":41.2,"expiration_date":"2029-03-22","underlying":"Common Stock","underlying_shares":5084},"source":{"system":"sec-edgar","filing":"0001209191-21-029066","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000120919121029066/doc4.xml","form_type":"4"}},{"id":2735741,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":128571,"kind":"person","name":"Dawson Michael John","position":1,"cik":"0001849790","reported_name":"Dawson Michael John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-29T21:46:49.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":20391,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in the Merger in exchange for a stock option to acquire 750,000 shares of LBS common stock for $1.45 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests according to the following schedule: 17% of the shares underlying the option vests on grant date and the remaining 83% vests in 10 quarterly installments thereafter beginning on September 30, 2018."}],"balance_after":20391,"derivative":{"exercise_price":53.33,"expiration_date":"2028-07-24","underlying":"Common Stock","underlying_shares":20391},"source":{"system":"sec-edgar","filing":"0001209191-21-029066","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000120919121029066/doc4.xml","form_type":"4"}},{"id":2735740,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":128571,"kind":"person","name":"Dawson Michael John","position":1,"cik":"0001849790","reported_name":"Dawson Michael John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-29T21:46:49.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":5438,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 200,000 shares of common stock of Leading BioSciences, Inc. (\"LBS\") for $0.75 per share, pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the \"Merger\").  Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock.  In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested in four equal quarterly installments from the vesting commencement date."}],"balance_after":5438,"derivative":{"exercise_price":27.59,"expiration_date":"2027-02-10","underlying":"Common Stock","underlying_shares":5438},"source":{"system":"sec-edgar","filing":"0001209191-21-029066","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000120919121029066/doc4.xml","form_type":"4"}}]}